Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Laboratory for Molecular Medicine, |
RCV000218419 | SCV000270625 | likely benign | not specified | 2015-12-17 | criteria provided, single submitter | clinical testing | p.Thr2122Thr in exon of 42 of NF1: This variant is not expected to have clinical significance because it does not alter an amino acid residue and is not located within the splice consensus sequence. |
Labcorp Genetics |
RCV001441436 | SCV001644367 | likely benign | Neurofibromatosis, type 1 | 2024-05-28 | criteria provided, single submitter | clinical testing | |
Genome- |
RCV001441436 | SCV002561210 | likely benign | Neurofibromatosis, type 1 | 2022-03-15 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002363063 | SCV002660571 | likely benign | Hereditary cancer-predisposing syndrome; Cardiovascular phenotype | 2020-12-02 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |